Burjeel Cancer Institute

What Burjeel Cancer Institute does

Burjeel Cancer Institute (BCI) is the flagship oncology arm of Burjeel Holdings — a publicly listed (ADX: Burjeel) UAE healthcare group — and operates the largest dedicated cancer care network in the GCC. Headquartered within Burjeel Medical City in Abu Dhabi, BCI runs a multidisciplinary oncology service line spanning prevention, screening, medical oncology (chemotherapy, immunotherapy, targeted therapy), radiation oncology, surgical oncology, nuclear medicine, bone marrow transplantation, palliative care and rehabilitation. Its technology stack combines da Vinci Xi robotic surgery, intraoperative MRI, Elekta Versa HD linear accelerator, PET-CT and SPECT-CT imaging, BrainLab planning, 3D/4K/ICG laparoscopic systems, AI-integrated pathology, and proprietary molecular platforms (Co-Lab, Onco-Helix), supporting advanced procedures such as Trucheck circulating tumor cell screening (70+ tumor types, >95% accuracy), ctDNA-based ESR1 mutation monitoring (SERENA-6), and GCC-first Hepatic Artery Infusion Pump implantation for colorectal liver metastases.

The institute serves over 5,000 oncology patients annually across a network that includes 5 hospitals and 16 clinics in Abu Dhabi, 2 hospitals and 8 clinics in Al Ain/Muzah, Dubai (2 hospitals, 1 clinic, plus the acquired ACOC), Sharjah, Al Dhafra, and Ajman, with additional reach into Oman. It treats both local UAE residents and international medical-tourism patients supported by a dedicated concierge team handling travel, visa, accommodation and second-opinion logistics. BCI generates clinical services revenue across inpatient and outpatient settings, supplemented by medical tourism and clinical-trial activity — 7 active trials and 150+ patients enrolled in international protocols over the past year, including Phase 3 ENERGIZE trials for thalassemia with AbbVie.

Operationally, BCI is anchored by an internationally trained multidisciplinary team led by CEO Prof. Humaid Al-Shamsi and is reinforcing its training pipeline through the UAE's first accredited oncology fellowship with Harvard Medical School and Dana-Farber Cancer Institute, alongside partnerships with the European Institute of Oncology, Children's Hospital of Philadelphia, and SJD Barcelona Children's Hospital. Technology partnerships with Paige.AI (FDA-approved AI pathology), Hippocratic AI (multilingual patient agents), and Kite Pharma (local CAR-T manufacturing at up to 90% lower cost than international pricing) are extending its AI diagnostics and advanced-therapy capabilities, while accreditation stack (JCI Gold, CAP, CARF, ESMO, TEMOS, EIAC, ISO 9001:2015) supports positioning as the regional standard-bearer for advanced oncology care.

Name

Burjeel Cancer Institute

Legal name

Burjeel Cancer Institute

Website

https://burjeelcancerinstitute.org

Company type

Public

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Burjeel Cancer Institute is the flagship oncology arm of publicly listed Burjeel Holdings and the largest dedicated cancer care network in the GCC. It delivers multidisciplinary oncology — screening, diagnostics, medical, radiation and surgical oncology, nuclear medicine and BMT — to over 5,000 patients annually across the UAE and Oman, serving both UAE residents and international medical-tourism patients.

Ownership category

akta.pro rank

Product category

Oncology Services

NAICS

Specialty (except Psychiatric and Substance Abuse) Hospitals (622310), Ambulatory Health Care Services (621)

SIC

Services-Hospitals (8060)

akta.pro primary industry

Hospital-Integrated Cancer Centers (Acute Oncology Programs) (HLAFAAAM)

akta.pro secondary industries

Oncology & Cancer Specialty Hospitals (HLAFAHAC), Ambulatory Oncology Centers (Outpatient Chemo/Radiation) (HLAFABAI), Oncology Specialty Pharmaceuticals (HLAIACAA)

Keywords

• Oncology treatment services
• Cancer diagnostic imaging
• Radiation therapy services
• Surgical oncology care
• Precision medicine oncology

Headquarters

HQ city

Abu Dhabi

HQ country

United Arab Emirates

HQ region

Middle East

Offices7 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales, Supply Chain

Revenue model

1. Clinical oncology services: Burjeel Cancer Institute generates revenue through the provision of comprehensive cancer care services including consultations, diagnostics, medical oncology (chemotherapy, immunotherapy, targeted therapy), radiation oncology, surgical oncology, nuclear medicine, bone marrow transplantation, palliative care, and rehabilitation. Services are delivered across inpatient and outpatient settings.
2. Medical tourism and international patient services: Revenue is generated from international patients seeking advanced oncology care in Abu Dhabi. The institute provides concierge services including travel coordination, accommodation, visa assistance, and second opinions — all contributing to the revenue base.
3. Clinical trials and early-access therapies: The institute enrolls patients in international clinical trial protocols (e.g., SERENA-6, ENERGIZE for thalassemia with AbbVie), providing access to investigational therapies while generating research-related revenue.

Go-to-market motion3 records

Distribution channels4 records

Marketing channels6 records

Core offering

Burjeel Cancer Institute (BCI) provides comprehensive multidisciplinary cancer care including medical oncology (chemotherapy, immunotherapy, targeted therapy), surgical oncology, radiation oncology, nuclear medicine, bone marrow transplantation, palliative care, and rehabilitation across a network of hospitals and clinics in the UAE and Oman. The institute operates specialized centers for breast cancer, sarcoma and bone tumors, and neuro-oncology, supported by advanced diagnostics (PET-CT, iMRI, molecular/genetic testing) and precision medicine platforms. BCI also offers non-invasive cancer screening (Trucheck), clinical trial enrollment, and dedicated international patient concierge services.

Product overview

Burjeel Cancer Institute (BCI), part of Burjeel Holdings, operates as the largest cancer care network in the GCC with facilities across Abu Dhabi, Al Ain, Dubai, Sharjah, Al Dhafra, and Oman, serving over 5,000 oncology patients annually and delivering over 10,000 radiotherapy sessions. The institute provides a unified platform combining multidisciplinary cancer care across medical oncology, surgical oncology, radiation oncology, bone marrow transplant, nuclear medicine, and palliative care, supported by specialized sub-products and centers including the Burjeel Breast Care Center, Neuro-Oncology Centre, Sarcoma & Bone Center, Co-Lab and Onco-Helix diagnostics, and the UAE's first dedicated Oncology Pharmacy. BCI also offers advanced treatment technologies including da Vinci Xi robotic surgery, Elekta Versa HD radiation therapy, PET-CT/SPECT-CT imaging, intraoperative MRI, 3D breast tomosynthesis, and BrainLab planning systems. The institute provides cancer screening via Trucheck (70+ tumor types), ctDNA-guided Camizestrant treatment (SERENA-6), and locally manufactured CAR-T cell therapies in partnership with Kite Pharma. International patients access BCI through dedicated concierge services including in-flight medical support, travel coordination, and flexible payment options. AI capabilities include Paige.AI FDA-approved pathology diagnostics, Hippocratic AI multilingual patient-facing agents, and predictive health management platforms.

Differentiator

Problem solved

Functional benefit

Products and services

• Sarcoma & Bone Center A specialized multidisciplinary center within BCI for diagnosing and treating rare bone and soft tissue tumors, leveraging advanced technologies and a team of specialists to improve survival outcomes and regional cancer care excellence.
• Neuro-Oncology Centre A multidisciplinary neuro-oncology center at Burjeel Medical City providing care for brain and nervous system tumors across all ages, featuring intraoperative MRI and neuronavigation systems for precise tumor removal.
• Burjeel Breast Care Center A comprehensive breast cancer center within BCI offering same-day appointments, 3D mammography (Hologic), AI-assisted imaging interpretation, surgical oncology, oncoplastics, reconstructive surgery, and a dedicated Survivorship Lounge for post-treatment support.
• Trucheck Cancer Screening A non-invasive blood test analyzing circulating tumor cells (CTCs) and molecular markers to detect over 70 types of solid tumors with accuracy exceeding 95%, including breast, lung, pancreatic, liver, thyroid, and gastrointestinal cancers. Recommended annually for individuals aged 40+.
• Co-Lab and Onco-Helix Genetic and Molecular Diagnostics Revolutionary cancer diagnostics and personalized treatment services providing molecular and genetic profiling to support tailored oncology care.
• International Patient Services (Medical Tourism Concierge) Comprehensive concierge services for international patients including in-flight medical experience, travel arrangements, visa assistance, accommodation coordination, flexible payment options, and ongoing post-visit care.
• Oncology Pharmacy The first dedicated oncology pharmacy in the UAE at Burjeel Cancer Institute, exclusively serving cancer patients with specialized medications and personalized counseling.
• Camizestrant Treatment (SERENA-6 Protocol) A next-generation oral SERD (selective estrogen receptor degrader) therapy for advanced breast cancer with ESR1 mutation, administered under the SERENA-6 protocol with ctDNA-guided molecular monitoring.
• CAR-T Cell Therapy Chimeric antigen receptor T-cell therapy manufactured locally through partnership with Kite Pharma, offering blood cancer and lymphoma treatments at up to 90% lower cost than international pricing.

Quantifiable outcome

• 56% reduction in risk of disease progression or death with Camizestrant vs. conventional endocrine therapy in ESR1-mutant breast cancer patients (SERENA-6 trial)
• +5 more outcomes

Named customers1 record

Segments5 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability9 records

Feature12 records

Partnerships

Twelve partnerships are on record, tiered moderate and core.

• Abu Dhabi Public Health Centre (ADPHC)moderateStrategic or Co-development Partner · 1 December 2025ADPHC, in collaboration with the Department of Health – Abu Dhabi and strategic partners, launched the Festival of Health 2025 (December 12–28) with 140+ activities promoting healthy living across Abu Dhabi. BCI participates as a healthcare partner.
• Axiom SpacemoderateStrategic or Co-development Partner · 1 September 2025Burjeel Holdings and Axiom Space collaborated on the 'Sweet Ride' research during the Ax-4 mission aboard the ISS, investigating diabetes management tools in space. Results showed continuous glucose monitors and insulin pens function effectively in microgravity — paving the way for diabetic astronauts and advancing remote healthcare monitoring.
• Harvard Medical School and Dana-Farber Cancer InstitutecoreStrategic or Co-development Partner · 1 April 2025Burjeel Cancer Institute launched the UAE's first accredited fellowship program in oncology in partnership with Harvard Medical School and Dana-Farber Cancer Institute, enhancing local oncology expertise and advancing cancer research and education in the region.
• AbbVie (ENERGIZE clinical trial)coreStrategic or Co-development Partner · 1 April 2025Burjeel Cancer Institute leads the Phase 3 ENERGIZE clinical trials for thalassemia in collaboration with AbbVie, enrolling patients in international protocols and providing access to investigational gene therapies for blood disorders.
• European Institute of Oncology (IEO)coreStrategic or Co-development Partner · 1 April 2025Partnership focuses on enhancing cancer patient care through clinical research and scientific programs, training and education for healthcare professionals, and high-level clinical services. Includes a distinguished visiting faculty network, nurse and pharmacist capacity-building initiatives, and an advisory board.
• Children's Hospital of Philadelphia (CHOP)coreStrategic or Co-development Partner · 1 April 2025Partnership enhances pediatric cancer care capabilities, advanced diagnostic services, remote consultations, and multidisciplinary second opinions. CHOP visiting programs support knowledge exchange in pediatric precision oncology.
• SJD Barcelona Children's HospitalcoreStrategic or Co-development Partner · 1 April 2025Partnership strengthens BCI's pediatric oncology care capabilities, providing ongoing remote support and medical mentorship, particularly for rare and complex pediatric cases.
• Department of Health – Abu DhabicoreStrategic or Co-development Partner · 1 April 2025The Department of Health – Abu Dhabi oversees and supports Burjeel Cancer Institute's clinical programs, including the landmark SERENA-6 Camizestrant trial. BCI operates under DoH regulatory supervision and collaborates on national health initiatives such as the Festival of Health 2025.
• Paige AIcoreTechnology or Integration · 1 April 2025Burjeel Holdings partnered with Paige (US-based AI company) to deploy FDA-approved AI pathology tools across its network, including Paige Prostate Detector (first FDA-authorized AI algorithm for prostate cancer detection), Paige Lymph Node Detector, and Paige OmniScreen. Addresses the global pathologist shortage and accelerates reliable cancer diagnostics.
• Keringing Cross (CAR-T therapy)coreStrategic or Co-development Partner · 1 April 2025Burjeel Holdings partnered with Keringing Cross (US nonprofit) to manufacture CAR-T cell therapies locally at up to 90% lower cost than current international prices. Supports technology, materials, specialized training, and lentiviral vectors for local CAR-T production, initially focusing on leukemia and lymphoma, with plans to expand to other diseases including HIV.
• Hippocratic AImoderateTechnology or Integration · 1 April 2025Burjeel Holdings partnered with Hippocratic AI to deploy multilingual, empathy-driven AI healthcare agents across its facilities in the UAE and Oman. Agents handle non-diagnostic clinical tasks including appointment scheduling, patient education, health risk assessments, and post-visit follow-up — in Arabic (including Emirati dialect), English, and 15+ other languages.
• Advanced Care Oncology Center (ACOC)coreChannel Partner/ Reseller/ Distributor · 1 April 2025Burjeel Holdings acquired an 80% stake in Advanced Care Oncology Center (ACOC) in Dubai for AED 92 million. ACOC specializes in radiation oncology and nuclear medicine. The acquisition strengthens BCI's radiation oncology network and establishes the ACOC brand across GCC countries.

Scale indicators11 records

Recent moves8 records

Expansion highlights6 records

Broad incumbents

• Saudi German Hospital Group: Saudi German Hospital Group operates large multi-specialty hospitals across the GCC including the UAE and Saudi Arabia with established oncology departments, representing a regional incumbent competing for medical tourism and insured oncology patients alongside BCI.
• King Faisal Specialist Hospital and Research Centre: KFSHRC is the leading tertiary cancer referral center in Saudi Arabia offering comprehensive multidisciplinary oncology, BMT, and clinical trials; a regional reference point for MENA oncology patients who might otherwise travel to BCI for advanced care.
• Aster DM Healthcare: Aster DM Healthcare operates hospitals, clinics, and pharmacies across the UAE, Oman, India, and other geographies with established oncology services, providing a broader regional incumbent comparable through oncology footprint, GCC presence, and outpatient scale that overlaps BCI's network.
• Mediclinic Middle East: Mediclinic operates multi-specialty hospitals across Dubai, Abu Dhabi, and other emirates including City Hospital and Mediclinic Airport Road with established oncology services, providing broader healthcare portfolios that overlap with BCI's cancer care on a hospital-network basis.

Direct peers

• American Hospital Dubai: American Hospital Dubai is a premium multi-specialty hospital in Dubai with a comprehensive cancer program and US-affiliated standards, directly competing with BCI's Dubai operations (including ACOC) for premium and international oncology patients.
• Cleveland Clinic Abu Dhabi: Cleveland Clinic Abu Dhabi operates a multidisciplinary oncology program as part of its multi-specialty hospital on Al Maryah Island, directly competing for premium and international oncology patients in the same Abu Dhabi catchment as BCI with overlapping sub-specialty offerings and US-grade accreditation.
• Sheikh Shakhbout Medical City (Mayo Clinic partnership): SSMC is a flagship tertiary hospital in Abu Dhabi operated with Mayo Clinic expertise providing comprehensive cancer care including medical oncology, radiation oncology, and surgical oncology, competing head-to-head with BCI for complex cases, government referrals, and international patients.
• Tawam Hospital (Johns Hopkins/SEHA): Tawam Hospital in Al Ain is a major oncology referral center within the SEHA network with a Johns Hopkins partnership, offering multidisciplinary cancer care, bone marrow transplant, and pediatric oncology that overlaps BCI's Al Ain branch and competes for the same UAE patient pool.

Emerging players

• European Institute of Oncology (IEO): IEO is a Monza-based global oncology reference center with which Burjeel has a strategic partnership; it represents a best-in-class European specialty oncology comparator and potential model for BCI's program development and clinical research strategy.
• Tata Memorial Hospital: Tata Memorial is one of the largest specialty cancer hospitals globally with high-volume multidisciplinary oncology, clinical trials, and BMT, serving as a scale and oncology-network comparator for BCI's GCC-wide ambitions and its value-based oncology positioning.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/BurjeelMediCity
• YouTubeyoutube.com/@BurjeelCancerInstitute
• Facebookfacebook.com/burjeelcancerinstitute
• LinkedInlinkedin.com/company/burjeelcancerinstitute
• Instagraminstagram.com/burjeel_cancer_institute

Compliance8 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Subsidiaries3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Burjeel Cancer Institute